Shots:
- KaNDy to receive $425M upfront, ~$450M milestones until launch followed by additional commercial milestones. The transaction is expected to be completed in Sept’2020
- The acquisition will add KaNDy’s menopause drug to Bayer’s portfolio. KaNDy has published results of its NT-814 in P-IIb study that demonstrated positive results in mod. to sev. vasomotor symptoms due to menopause with expected initiation of its P-III studies in 2021
- Additionally, in early 2020, Bayer expands its partnership with Evotec to develop multiple clinical candidates for the PCOS and enters an exclusive license agreement with Daré for Ovaprene which is an investigational hormone-free monthly vaginal contraceptive, currently in development for the prevention of pregnancy in the US
Click here to read full press release/ article | Ref: Bayer | Image: KaNDy
Related News: Bayer Signs an Exclusive Option to License Agreement with Dare Biosciences to Commercialize Ovaprene in the US
